Glenmark Pharmaceuticals (NSE:GLENMARK, BOM:532296) said its wholly owned subsidiary Glenmark Specialty has launched acne treatment Winlevi across several European markets, according to a Thursday filing on Indian exchanges.
The company has started direct commercialization of the product in markets including Spain, the Nordic region and Central and Eastern Europe, while the launch in Portugal is being carried out through a strategic partner, the filing said.
The European Commission granted approval for Winlevi to Cassiopea, a subsidiary of Cosmo Pharmaceuticals, in October 2025, to treat acne vulgaris in adults and adolescents, according to the filing.